(function(){var loadHandler=window['sl_{21FEF8D7-4385-4DEB-B34B-7A4BB675EF9A}'];loadHandler&&loadHandler(15, '<div id="spr0_15873f93"><div id="spr1_15873f93" class="kern slide"><img id="img3_15873f93" src="data/img8.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_15873f93" class="kern slide"><img id="img0_15873f93" src="data/img17.png" width="721.48" height="46.226" alt="" style="left:-0.439px;top:493.774px;"/><div id="spr3_15873f93" style="left:-0.439px;top:493.774px;"><div style="width:0px;"><span id="txt0_15873f93" class="nokern" data-width="203.496094" style="left:7.2px;top:17.578px;">          MACE = Major Adverse Cardiovascular Events</span></div></div><img id="img1_15873f93" src="data/img33.png" width="721.48" height="82.286" alt="" style="left:-0.439px;"/><div id="spr4_15873f93" style="left:657.715px;top:502.143px;"><img id="img2_15873f93" src="data/img3.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr5_15873f93" style="left:8.298px;top:16.545px;"><div style="width:0px;"><span id="txt1_15873f93" data-width="539.630859" style="left:85.976px;top:5.272px;">Summary: PCSK9 inhibitor CVOT Data</span></div></div><div id="spr6_15873f93" style="left:22.286px;top:86.571px;"><div style="width:0px;"><span id="txt2_15873f93" class="nokern relpos" style="left:7.2px;top:46.105px;"></span><span id="txt3_15873f93" class="relpos" data-width="650.876953" style="left:21.389px;top:45.463px;">PCSK9i represent the most effective way of lowering LDL-C in a</span></div><div style="width:0px;"><span id="txt4_15873f93" data-width="597.296875" style="left:34.2px;top:79.063px;">broad cross-section of patients with clinical cardio-vascular</span></div><div style="width:0px;"><span id="txt5_15873f93" data-width="524.562500" style="left:34.2px;top:112.663px;">disease or those with familial hypercholesterolemia.</span></div><div style="width:0px;"><span id="txt6_15873f93" class="nokern relpos" style="left:7.2px;top:153.625px;"></span><span id="txt7_15873f93" class="relpos" data-width="619.568359" style="left:21.389px;top:152.983px;">Clinical trials with PCSK9i demonstrate efficacy and safety of</span></div><div style="width:0px;"><span id="txt8_15873f93" data-width="556.582031" style="left:34.2px;top:186.583px;">LDL-C lowering by an additional 60% on top of statin ±</span></div><div style="width:0px;"><span id="txt9_15873f93" data-width="587.097656" style="left:34.2px;top:220.183px;">ezetimibe therapy resulting in further reductions in MACE.</span></div><div style="width:0px;"><span id="txt10_15873f93" class="nokern relpos" style="left:7.2px;top:261.145px;"></span><span id="txt11_15873f93" class="relpos" data-width="635.673828" style="left:21.389px;top:260.503px;">The use of PCSK9i is recommended on top of statin therapy in</span></div><div style="width:0px;"><span id="txt12_15873f93" data-width="647.117188" style="left:34.2px;top:294.103px;">high risk cardio-vascular patients to enable lowering of the LDL-</span></div><div style="width:0px;"><span id="txt13_15873f93" data-width="266.738281" style="left:34.2px;top:327.703px;">C to recommended levels.</span></div></div></div></div>');})();